Dyadic International And Proliant Health And Biologicals Announce Recombinant Albumin Development And Commercialization Partnership; Dyadic Will Receive An Upfront Milestone Payment Of $1.5M
Portfolio Pulse from Benzinga Newsdesk
Dyadic International (NASDAQ: DYAI) has entered into a partnership with Proliant Health and Biologicals to develop and commercialize recombinant albumin products. Dyadic will receive an upfront milestone payment of $1.5 million and a share of profits from sales.
June 28, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dyadic International has entered into a partnership with Proliant Health and Biologicals to develop and commercialize recombinant albumin products. Dyadic will receive an upfront milestone payment of $1.5 million and a share of profits from sales.
The partnership with Proliant Health and Biologicals is likely to positively impact Dyadic's stock price in the short term due to the immediate financial benefit of the $1.5 million milestone payment and the potential for future profit shares from product sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100